Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease.
Journal: Journal of clinical pharmacology
Published: March 31, 2026
Severe gastrointestinal adverse reactions including perforation, ulceration, hemorrhage, and obstruction: A fumaric acid ester class new safety risk.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: February 11, 2025
Progressive multifocal leukoencephalopathy associated with sphingosine-1-phosphate receptor modulators: A large case series.
Journal: Multiple sclerosis and related disorders
Published: September 30, 2024
Immune-mediated colitis associated with ocrelizumab: A new safety risk.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: September 14, 2023
Grief-induced reversible cerebral vasoconstriction syndrome (RCVS).
Journal: BMJ case reports
Published: January 31, 2020
Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations.
Journal: Neurology and therapy
Published: September 04, 2019
Showing 1-7 of 7
Last Updated: 09/26/2026